BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 26189978)

  • 1. Medication taking behaviors among breast cancer patients on adjuvant endocrine therapy.
    Kimmick G; Edmond SN; Bosworth HB; Peppercorn J; Marcom PK; Blackwell K; Keefe FJ; Shelby RA
    Breast; 2015 Oct; 24(5):630-6. PubMed ID: 26189978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Higher symptom burden is associated with lower function in women taking adjuvant endocrine therapy for breast cancer.
    Sitlinger A; Shelby RA; Van Denburg AN; White H; Edmond SN; Marcom PK; Bosworth HB; Keefe FJ; Kimmick GG
    J Geriatr Oncol; 2019 Mar; 10(2):317-321. PubMed ID: 30553719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors associated with intentional and unintentional non-adherence to adjuvant endocrine therapy following breast cancer.
    Brett J; Fenlon D; Boulton M; Hulbert-Williams NJ; Walter FM; Donnelly P; Lavery B; Morgan A; Morris C; Watson E
    Eur J Cancer Care (Engl); 2018 Jan; 27(1):. PubMed ID: 27901302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Barriers to and facilitative processes of endocrine therapy adherence among women with breast cancer.
    Bright EE; Petrie KJ; Partridge AH; Stanton AL
    Breast Cancer Res Treat; 2016 Jul; 158(2):243-51. PubMed ID: 27342455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perceptions, Attributions, and Emotions Toward Endocrine Therapy in Young Women with Breast Cancer.
    Walker HE; Rosenberg SM; Stanton AL; Petrie KJ; Partridge AH
    J Adolesc Young Adult Oncol; 2016 Mar; 5(1):16-23. PubMed ID: 26812461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identifying socio-demographic and clinical characteristics associated with medication beliefs about aromatase inhibitors among postmenopausal women with breast cancer.
    Salgado TM; Davis EJ; Farris KB; Fawaz S; Batra P; Henry NL
    Breast Cancer Res Treat; 2017 Jun; 163(2):311-319. PubMed ID: 28251384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endocrine therapy for breast cancer: assessing an array of women's treatment experiences and perceptions, their perceived self-efficacy and nonadherence.
    Wouters H; Stiggelbout AM; Bouvy ML; Maatman GA; Van Geffen EC; Vree R; Nortier JW; Van Dijk L
    Clin Breast Cancer; 2014 Dec; 14(6):460-467.e2. PubMed ID: 24981234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-reported Adherence to Adjuvant Aromatase Inhibitor Therapy Using the Morisky Medication Adherence Scale: An Evaluation of Predictors.
    Kesmodel SB; Goloubeva OG; Rosenblatt PY; Heiss B; Bellavance EC; Chumsri S; Bao T; Thompson J; Nightingale G; Tait NS; Nichols EM; Feigenberg SJ; Tkaczuk KH
    Am J Clin Oncol; 2018 May; 41(5):508-512. PubMed ID: 27322700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adherence to Adjuvant Endocrine Therapy in Women With Breast Cancer: A Prospective Observational Study in Japanese Women.
    Kuba S; Maeda S; Matsumoto M; Yamanouchi K; Yano H; Morita M; Sakimura C; Hatachi T; Tokai Y; Takatsuki M; Fujioka H; Hayashida N; Nagayasu T; Eguchi S
    Clin Breast Cancer; 2018 Apr; 18(2):150-156. PubMed ID: 29290564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. More than just side-effects: The role of clinical and psychosocial factors in non-adherence to tamoxifen.
    Moon Z; Moss-Morris R; Hunter MS; Hughes LD
    Br J Health Psychol; 2017 Nov; 22(4):998-1018. PubMed ID: 28940998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding Breast Cancer Survivors' Beliefs and Concerns About Adjuvant Hormonal Therapy: Promoting Adherence.
    Hurtado-de-Mendoza A; Jensen RE; Jennings Y; Sheppard VB
    J Cancer Educ; 2018 Apr; 33(2):436-439. PubMed ID: 28205022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modifiable risk factors for adherence to adjuvant endocrine therapy among breast cancer patients.
    Jacob Arriola KR; Mason TA; Bannon KA; Holmes C; Powell CL; Horne K; O'Regan R
    Patient Educ Couns; 2014 Apr; 95(1):98-103. PubMed ID: 24492157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adherence to adjuvant endocrine therapy in postmenopausal breast cancer patients: A 5-year prospective study.
    Hagen KB; Aas T; Kvaløy JT; Søiland H; Lind R
    Breast; 2019 Apr; 44():52-58. PubMed ID: 30641300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonadherent behaviors among young women on adjuvant endocrine therapy for breast cancer.
    Wassermann J; Gelber SI; Rosenberg SM; Ruddy KJ; Tamimi RM; Schapira L; Borges VF; Come SE; Meyer ME; Partridge AH
    Cancer; 2019 Sep; 125(18):3266-3274. PubMed ID: 31120571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psychosocial factors related to non-persistence with adjuvant endocrine therapy among women with breast cancer: the Breast Cancer Quality of Care Study (BQUAL).
    Hershman DL; Kushi LH; Hillyer GC; Coromilas E; Buono D; Lamerato L; Bovbjerg DH; Mandelblatt JS; Tsai WY; Zhong X; Jacobson JS; Wright JD; Neugut AI
    Breast Cancer Res Treat; 2016 May; 157(1):133-43. PubMed ID: 27086286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adherence to Adjuvant Aromatase Inhibitor Therapy Among Postmenopausal Hispanic/Latino Women With Breast Cancer.
    Philipovskiy A; Campbell A; Heydarian R; Castillo B; Dwivedi AK; McCallum R; Aguilera R; Gaur S; Nahleh Z
    Anticancer Res; 2020 Feb; 40(2):857-864. PubMed ID: 32014929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Partner status moderates the relationships between sexual problems and self-efficacy for managing sexual problems and psychosocial quality-of-life for postmenopausal breast cancer survivors taking adjuvant endocrine therapy.
    Dorfman CS; Arthur SS; Kimmick GG; Westbrook KW; Marcom PK; Corbett C; Edmond SN; Shelby RA
    Menopause; 2019 Aug; 26(8):823-832. PubMed ID: 30994574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Race and Patient-reported Symptoms in Adherence to Adjuvant Endocrine Therapy: A Report from the Women's Hormonal Initiation and Persistence Study.
    Sheppard VB; Sutton AL; Hurtado-de-Mendoza A; He J; Dahman B; Edmonds MC; Hackney MH; Tadesse MG
    Cancer Epidemiol Biomarkers Prev; 2021 Apr; 30(4):699-709. PubMed ID: 33514603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identifying adherence barriers to oral endocrine therapy among breast cancer survivors.
    Paranjpe R; John G; Trivedi M; Abughosh S
    Breast Cancer Res Treat; 2019 Apr; 174(2):297-305. PubMed ID: 30523459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perceived barriers to treatment predict adherence to aromatase inhibitors among breast cancer survivors.
    Brier MJ; Chambless DL; Gross R; Chen J; Mao JJ
    Cancer; 2017 Jan; 123(1):169-176. PubMed ID: 27570979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.